Countries with high circumcision prevalence have lower prostate cancer mortality

Mitchell S Wachtel¹, Shengping Yang¹, Brian J Morris²

The present study determined the relationship of male circumcision (MC) prevalence with prostatic carcinoma mortality rate in the 85 countries globally for which data on each were available. MC prevalence in different countries were obtained from a WHO report and allocated to WHO categories of 81%–100%, 20%–80%, and 0%–19%. Prostatic carcinoma mortality data were from Globoscan, gross national income per capita as well as male life expectancy were from a World Bank report, and percentages of Jews and Muslims by country were from the Pew Research Institute and the North American Jewish Data Bank. Negative binomial regression was used to estimate prostatic carcinoma mortality rate ratios. Compared to countries with 81%–100% MC prevalence, prostatic carcinoma mortality rate was higher in those with MC prevalence of 0%–19% (adjusted OR [adjOR] = 1.82; 95% CI 1.14, 2.91) and 20%–80% (adjOR = 1.80; 95% CI, 1.16, 2.78). Higher Muslim percentage (adjOR = 0.92 [95% CI 0.87, 0.98] for each 10% increase) and longer life expectancy (adjOR = 0.82 [95% CI 0.72, 0.93] for each 5 additional years) were associated with lower prostatic carcinoma mortality. Higher gross national income per capita (adjOR = 1.10 [95% CI 1.01, 1.20] for double this parameter) correlated with higher mortality. Compared with American countries, prostatic carcinoma mortality rate was similar in Eastern Mediterranean countries (adjOR = 1.02; 95% CI 0.58, 1.76), but was lower in European (adjOR = 0.60; 95% CI 0.50, 0.74) and Western Pacific countries (adjOR = 0.54, 95% CI 0.37, 0.78). Thus, prostate cancer mortality is significantly lower in countries in which MC prevalence exceeds 80%.

Asian Journal of Andrology (2016) 18, 39–42; doi: 10.4103/1008-682X.159713; published online: 28 August 2015

Keywords: circumcision; country comparisons; epidemiology; global; prostate cancer; public health; urology

INTRODUCTION
Prostate cancer is the second most common cancer in men after lung cancer.¹ Previous studies of the relationship of male circumcision (MC) and prostatic carcinoma incidence have either used small sample sizes²–⁴ and/or a single locality.⁵ In a previous evaluation in the current journal of 178 countries, the last author and a colleague found an association between prostatic carcinoma incidence and MC prevalence, but that study did not adjust for potential confounding variables.⁶ To date, an association study of MC prevalence with death arising from prostatic carcinoma globally has not been performed.

The aim of the present study was to determine the association of prostatic carcinoma mortality rate with the prevalence of MC in the 85 countries in the world for which data on each were available. The study used adjustments for potential confounding factors such as the percentages of countries that were predominantly Muslim or Jewish, gross national income, life expectancy, and geographical region.

MATERIALS AND METHODS
Prevalence data for MC for various countries were obtained from a report in 2006 by the World Health Organization (WHO) and were grouped into WHO categories of <20%, 20%–80%, and >80% MC prevalence (see Figure 4 of the WHO document).⁷ Prostate cancer deaths per 100 000 man-years (age-standardized mortality rate), and characterizations of data sources were obtained from a report in 2012 by the International Agency for Research on Cancer⁸ and logarithms of quotients of deaths served as offsets for mortality rates in regression analyses. The 2012 gross national income per capita and data on male life expectancy at birth were obtained from a report by the World Bank,⁹ with logarithms of gross national income per capita entered into regression analyses. Estimates of prevalence in 2010 of Jews in different countries were obtained from the North American Jewish Data Bank and for Muslims from the Pew Research Center.¹⁰ Negative binomial regression¹¹ was used to calculate estimates and standard errors of the regression coefficients. The outcome, or Y, variable was the number of prostate cancer deaths, adjusted by means of an offset for the population of each country. The predictor, or X, variables were (1) male circumcision prevalence, (2) percentages of countries that were Muslim, (3) percentages of countries that were Jewish, (4) gross national income, and (5) WHO region. Analyses were performed with the MASS package¹² on R 3.1.2.¹³ Null hypotheses were rejected for P < 0.05.

RESULTS
We evaluated the distributions of 197 434 prostatic carcinoma deaths among 85 countries with known gross national income per capita, male life expectancies, incidence of prostatic carcinoma death obtained from complete cancer registry data reported by the International

¹Department of Pathology, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA; ²School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia. Correspondence: Prof. Emeritis BJ Morris (brian.morris@sydney.edu.au)
Received: 30 January 2015; Revised: 15 March 2015; Accepted: 26 March 2015
Agency for Research on Cancer, and MC prevalence data reported by the WHO.

Figure 1 shows mortality by MC and religious orientation prevalence. Countries with >81% MC prevalence had lower prostatic carcinoma mortality rate than countries with lower MC prevalence. The incidence of death appeared to decline as the percentage of Muslims increased. This did not appear to be the case for the percentage of Jews, although it is important to note that no country apart from Israel has even a modest percentage of Jews.

Figure 2 shows mortality by gross national income per capita, life expectancy, and geographical region. A very minimal increment in mortality is seen with greater gross national income per capita. A slight trend of lower mortality appears with higher life expectancy. North, Central, and South American (hereafter, “American”) countries appeared to have higher mortality than did European, Eastern Mediterranean, and Western Pacific countries.

Figure 3 shows results of negative binomial regression. Values in the diagram are adjusted odds ratios (adjOR), with 95% confidence intervals (CI) shown as horizontal lines. As is the convention, when a CI line does not cross the vertical dotted line, the corresponding OR was deemed statistically significant (P < 0.05, Wald’s χ² test). The incidence of prostatic carcinoma death for countries in which MC prevalence was 0%–19% was 82% higher than that of countries in which MC prevalence was >80% (adjOR = 1.82; 95% CI 1.14, 2.91). Similar results were obtained when comparing high prevalence MC countries with countries having an MC prevalence of 20%–80% (adjOR = 1.80; 95% CI, 1.16, 2.78). The higher the percentage of Muslims in a country the lower the prostatic carcinoma mortality (adjOR = 0.92 [95% CI 0.87, 0.98] for each 10% increase in percentage of Muslims). Failure to find a similar association for Jews might have been due to lower population prevalence and thus power of the analysis (P > 0.05). A barely statistically significant association was found for higher gross national income (adjOR = 1.10 [95% CI 1.01, 1.20] for double the gross national income). Longer life expectancy was associated with lower incidence of prostatic carcinoma death (adjOR = 0.82 [95% CI 0.72, 0.93] for 5 years increase in lifespan). Owing to the availability of data from only two countries in each of Africa and South East Asia, no conclusion could be made about prostatic carcinoma, gross national income per capita, and life expectancy specifically in these regions. Eastern Mediterranean countries had similar prostatic carcinoma mortality incidence as American countries (adjOR = 1.02; 95% CI 0.58, 1.76), while for European (adjusted OR = 0.60; 95% CI 0.50, 0.74) and Western Pacific (adjOR = 0.54, 95% CI 0.37, 0.78) countries prostatic carcinoma mortality was lower. Because the analysis was multivariate, each odds ratio took into account the findings of the other analyses. Differences in mortality with respect to MC prevalence were adjusted for percentages of Muslims and Jews, for gross national income per capita, for male life expectancy at birth, and for WHO region.

Neither violations of assumptions of generalized linear model regression nor important outliers were detected.

DISCUSSION

The present study found that prostatic carcinoma mortality rate in countries in which MC prevalence was >80% was approximately 45% lower than in countries in which MC prevalence was <80%. Living in a country with a higher percentage of Muslims, a lower gross national income per capita, longer life expectancy, and elsewhere than the Americas or Western Europe was associated with lower prevalence of prostatic carcinoma death. Our findings are consistent with, but do not prove, the hypothesis that MC affords a protective effect against prostatic carcinoma mortality.

Besides prostatic carcinoma incidence, inter-country comparisons have shown MC prevalence to be associated with a reduction in penile carcinoma. The various case-control studies that have reported an
association between MC and reduced prevalence of prostatic carcinoma include the following. The first, in 1951, found that in men operated on for prostatic obstruction, only 1.8% of obstructions were cancerous in Jews, a group in which virtually all males are circumcised, compared with 19% in gentiles. Subsequent studies in Sweden, Southern California, and the UK found prostatic carcinoma prevalence was 50%-62% lower in circumcised men compared with uncircumcised men. These earlier studies were, however, small, comprising 100–300 subjects per group. A study in Seattle in 2012 comprising 1754 cases and 1645 controls found that MC was associated with an 18% reduction in aggressive prostatic carcinoma and a 12% reduction in less aggressive prostatic carcinoma, but only if the circumcision had been performed prior to sexual debut. The study found, moreover that the protective effect of MC was not affected by socioeconomic status. In 2014 a study in Montreal involving 1590 cases and 1618 controls found that MC was associated with an 18% reduction in prostatic carcinoma, but only if the circumcision had been performed prior to sexual debut and had been performed early in life.

Prostate-specific antigen screening, available in some, but not all, high gross national income countries, by detecting more prostate tumors, generates higher prevalence data for prostatic carcinoma. Because the present study concerned incidence of prostatic carcinoma mortality, not incidence of prostatic carcinoma itself, this potential confounding variable was not an issue in our analyses.

All epidemiology studies, including this one, suffer from the modifiable areal unit problem (MAUP), sometimes referred to as the “ecological” problem. The MAUP exists because results taken at different area levels can reveal different results. Thus, an analysis of all the countries of Western Europe might produce different patterns than analyses of all the provinces of European countries. No epidemiological study can draw definite conclusions at the individual level. On the other hand, when policy considerations are made at national levels, country comparisons are precisely what matters. National comparisons such as the landmark one by Doll on the relationship between cigarette smoking and lung cancer retain their utility, even though they do not themselves prove a relationship at the individual level. The present study, while not proving that men who are circumcised bear a lesser risk of developing prostate cancer, does add to the evidence that policy changes at the national level to encourage MC will likely be associated in the long run with decreasing rates of death from prostate cancer.

Although the mechanism of the protective effect of MC against prostatic carcinoma is yet to be defined, an infectious pathway has been considered. Since MC confers varying degrees of protection against certain common sexually transmitted infections (STIs), the reduced prostatic carcinoma incidence in men circumcised early in life lends support to findings that history of STIs increases risk of prostate cancer by 48%. In the US Physicians Health Study prevalence of the most common STI, Trichomonas vaginalis, was associated with risk of prostatic carcinoma later in life. Risk was two-fold higher for advanced prostatic carcinoma and three-fold higher for terminal cases. T. vaginalis is symptomless in most men carrying these infectious organisms, and a randomized controlled trial found MC reduced risk of T. vaginalis infection by 59%. Although there is no convincing evidence for a role of oncogenic types of HPV in prostate cancer etiology, a recent study noted that the presence of HPV16 in prostate tumor biopsies was associated with earlier death. A meta-analysis of 46 studies published between 1971 and 2011 found ever having had an STI to be associated with a 49% higher relative risk of prostatic carcinoma, relative risk of gonorrhea being 20% higher, but data for 3 studies of T. vaginalis (presumably included within the “any STI” group) were not reported. In potential contrast, the group in Montreal found that, in their cohort, those men having had more than 20 lifetime female sexual partners had a 28% lower risk of prostatic carcinoma, whereas having had several male sexual partners increased the risk.

Confounding factors include the following. The association between MC and reduced prostatic carcinoma mortality with increased percentage of Muslims in a population could alternatively reflect any one of a number of cultural or genetic factors such as, for example, dietary customs or the Islamic prohibition of alcohol. Another dietary factor is high red meat consumption by more affluent populations. This increases risk of several cancers, in part involving metabolites of methionine, an amino acid that is much lower in vegan diets. In the case of prostatic carcinoma some studies, but not others, have implicated red meat consumption as a factor. Attempting to adjust for country-specific differences in dietary factors was, however, deemed too complicated and beyond the limit of the number of variables that could be incorporated into our multivariable analysis.

The association of decrease in prostatic carcinoma mortality with increased life expectancy may reflect the major impact that prostatic carcinoma has on male mortality. Prostate cancer is the second most common cancer in men after lung cancer. Because prostatic carcinoma is common in older men a decrease in prostatic carcinoma mortality should increase male lifespan. Although this notion, as well as the benefit of prostate-specific antigen (PSA) screening, has been

---

**Figure 3:** Results of negative binomial regression.
questioned, more recent analyses found that PSA screening reduced the rate of prostatic carcinoma death and that discontinuation of PSA screening would likely increase the number of deaths due to prostatic carcinoma. The increased (competing) risk of dying from other age-related diseases might, however, partially explain the reduced rate of prostatic carcinoma death in screened subjects.

Our geographical findings may reflect any number of differences. A factor contributing to higher risk of prostatic carcinoma death in Middle Eastern and American countries could be racial since Black men have an elevated risk of prostatic carcinoma compared with white men.

The negative impact we found of gross national income per capita on lower prostatic carcinoma mortality might reflect factors associated with higher living standards. Obesity appears to be a major factor, most likely contributed by factors such as Western sedentary lifestyle and diet.

Future directions for research on risk factors for prostatic carcinoma include (i) better analyses of specific effects of alcohol to ascertain with greater certainty whether or not this is indeed a risk factor, (ii) dietary analyses that examine the quantity as well as the specific types of meats and other protein sources consumed, (iii) molecular studies of the relationship of prostate carcinogenesis to those STIs which MC is known to protect against and (iv) determination of the specific factors that might explain why an increase in gross national income per capita results in a modest increment in death from prostatic carcinoma.

CONCLUSION
By use of negative binomial regression analyses adjusting for potential confounding factors, the present study has shown for the first time that prostatic carcinoma mortality rate is lower in countries that have an MC prevalence of >80%. Lower prostatic cancer death was found in countries with a higher percentage of Muslims, a lower gross national income per capita, longer life expectancy, and elsewhere than the Americas or Western Europe. Our findings are consistent with, but do not prove, the hypothesis that MC affords a protective effect against prostatic carcinoma mortality.

AUTHOR CONTRIBUTIONS
MSW conceived the project and provided statistical evaluation, drafting of the manuscript and intellectual input; SY performed statistical analyses, intellectual input and critical review of drafts; BJM provided the final manuscript and intellectual input; SY performed statistical evaluation, drafting of the specific factors that might explain why an increase in gross national income per capita results in a modest increment in death from prostatic carcinoma.

COMPETING INTERESTS
All authors declare no competing interests.

REFERENCES
1 Feeney J, Shih RR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–917.
2 Rivach A, Ravich RA. Prophylaxis of cancer of the prostate, penis, and cervix by circumcision. N Y State J Med 1951; 51: 1519–1520.
3 Apt A. Circumcision and prostatic cancer. Acta Med Scand 1965; 178: 493–504.
4 Ross RK, Shimizu H, Paganini-Hill A, Honda G, Henderson BE. Case-control studies of prostate cancer in blacks and whites in Southern California. J Natl Cancer Inst 1987; 78: 869–74.
5 Ewing P, Bowie C. A case-control study of cancer of the prostate in Somerset and East Devon. Br J Cancer 1996; 74: 661–6.